LGALS9 and neoplasm: The results (Fig. 6j) showed that compared with the “FSGG/siGL2+M” treatment, tumor-Ag-specific T cell response was increased only 29.41% by the “FSGG/siGL2+Laser+M” treatment due to photothermal effects, and only 29.59% by the “FSGG/siGal-9+M” treatment after knocking down Gal-9, but 91.23% by the “FSGG/siGal-9+Laser+M” treatment which further verified the synergistic FSGG/siGal-9 photothermal-immunotherapy.